• G Cavaletti, D R Cornblath, I S J Merkies, T J Postma, E Rossi, B Frigeni, P Alberti, J Bruna, R Velasco, A A Argyriou, H P Kalofonos, D Psimaras, D Ricard, A Pace, E Galiè, C Briani, C Dalla Torre, C G Faber, R I Lalisang, W Boogerd, D Brandsma, S Koeppen, J Hense, D Storey, S Kerrigan, A Schenone, S Fabbri, M G Valsecchi, and CI-PeriNomS Group.
• Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy. guido.cavaletti@unimib.it
• Ann. Oncol. 2013 Feb 1; 24 (2): 454-62.

BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study.Patients And MethodsAfter literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out.ResultsGood inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures.ConclusionGood validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.

12 keywords...

hide…